Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B | $3.72B |
| Cost of revenue | $576.50M | $669.40M | $584.60M | $521.60M | $530.20M | $464.30M | $565.40M | $491.10M |
| Gross profit | $3.71B | $2.94B | $3.30B | $3.23B | $3.15B | $2.56B | $3.22B | $3.23B |
| Gross margin | 86.6% | 81.4% | 84.9% | 86.1% | 85.6% | 84.7% | 85.1% | 86.8% |
| Research and development | $1.76B | $1.65B | $1.64B | $1.56B | $1.43B | $1.34B | $1.43B | $1.33B |
| Selling, general and administrative | $662.10M | $647.70M | $775.00M | $657.80M | $634.20M | $633.00M | $792.20M | $714.40M |
| Operating expenses | $2.42B | $2.29B | $2.43B | $2.21B | $2.07B | $1.97B | $2.18B | $2.05B |
| Operating income | $1.29B | $642.90M | $869.90M | $1.03B | $1.08B | $591.70M | $1.04B | $1.18B |
| Operating margin | 30.1% | 17.8% | 22.4% | 27.3% | 29.4% | 19.5% | 27.5% | 31.7% |
| EBITDA | $1.42B | $766.10M | $1.01B | $1.16B | $1.21B | $718.60M | $1.17B | $1.30B |
| Interest expense | −$11.00M | −$12.90M | −$12.20M | −$19.30M | −$3.60M | −$8.70M | −$10.50M | −$13.80M |
| Income before taxes | $1.53B | $831.20M | $1.04B | $1.76B | $1.52B | $905.00M | $958.10M | $1.49B |
| Income taxes | $230.90M | $104.00M | $199.10M | $303.30M | $127.10M | $96.30M | $40.40M | $152.40M |
| Net income | $1.30B | $727.20M | $844.60M | $1.46B | $1.39B | $808.70M | $917.70M | $1.34B |
| Net margin | 30.2% | 20.2% | 21.7% | 38.9% | 37.9% | 26.7% | 24.2% | 36.0% |
| EPS, basic | $12.62 | $6.99 | $8.20 | $14.09 | $13.24 | $7.58 | $8.53 | $12.40 |
| EPS, diluted | $12.23 | $6.75 | $7.86 | $13.62 | $12.81 | $7.27 | $8.07 | $11.54 |
| Diluted shares | 106.00M | 107.70M | 107.40M | 107.20M | 108.60M | 111.20M | 113.70M | 116.20M |
Figures describe Regeneron Pharmaceuticals shares, not any token. As of Jul 30, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.